Over the past five years, the cosmetic industry has met with several legislative changes. Within the new legislative package, including the new REACH and CLP, it is important to find a comfortable routine that will minimize costs while staying effective and compliant with all regulations.
Article by David Townson, Global Oncology Executive Director, Novartis
For those practitioners in the field of Portfolio Management an interesting article can be found in Forbes'.com written by Bruce Booth, “If I Were a Big Pharma Head of R&D…”. The article offers a perspective on the productivity problems with the pharmaceutical industry, and most interestingly, proposed solutions – many of which fall within the purview of Portfolio Management.
Mr. Booth cites the “ossified, risk-avoiding, ‘analysis-paralysis’ culture” as a major contributor to the lack of productivity in big pharma and there is more than a subtle pointing-the-finger at field of Portfolio Management. Interestingly, the article paradoxically cites the strength of the various tools of analysis that are used commonly in Portfolio Management – which he believes have become “nearly un-challengeable” – as a key culprit for the productivity dilemma. These systems, processes, and people responsible for helping organizations understand the risks, values, and opportunities within their portfolios have essentially lobotomized our leaders. One gets the vision of our cowering risk-averse big pharma leaders being presented with a one-sided view with systems that practically make the decisions for them by pre-defining rules for investment decision-making, essentially leaving their hands-tied. By objectively (and admittedly not always accurately) measuring risk, value, and probabilities Portfolio Management has removed the risk-taking from R&D.
But I see it differently. Portfolio Management informs decision-makers of the potential risks, value, and probabilities of success of its various assets. However, if our leaders are incentivized to deliver short-term “productivity” (a term which is not static in itself) at the expense of funding the future it is not the Portfolio Management systems which are at fault, but rather it is the forces that define what “productivity” is for that company, at that time, which hold responsibility. If I decide not to embark upon a trip when a hurricane is forecasted to hit the area I don’t blame the weather forecaster for informing me of the risk do I? Regardless of whether the carrot-holder for big pharma’s leaders is Wall Street, a Board of Directors, or whomever, Portfolio Management, if done correctly, does not stack the deck for or against any one type of investment. And here is where I find myself agreeing with Mr. Booth: The productivity gaps that many companies are suffering have been the result of a mindset bent on defining “productivity” using too many short-term measures at the expense of a more sustainable approach which would take more risk, albeit, intelligently.
Interested in this topic?
Advanced Protein Aggregation & Characterization
This training will focus on occurrence of particles in drug products, effects of protein aggregates, critical process and parameters. Attendees will gain overview of on utility and limits of predictive experiments, learn concerns from the authorities and relevant aggregation guidelines, and more.
Corporate Compliance & Transparency in the Pharmaceutical Industry
This two-day conference will serve as a platform for an open and dynamic dialogue with HCPs and patients to achieve common goals. Learn how to embed compliance in the business and develop one simple system for managing compliance & transparency in a complex and regulated environment.
Quality in Pharma & Biotech
Join the senior quality experts & regulators to understand how to close the loop in your desired level of quality. Gain critical insights into new regulatory expectations, process simplification and robustness, lean six sigma, MHRA & FDA inspection approach and reach higher quality effectively.